Molina Healthcare Inc (MOH)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-14. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 5.95% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3?
- Analysts Estimate Molina (MOH) to Report a Decline in Earnings: What to Look Out for
- Centene vs. Molina: Which Managed Care Stock Has More Upside?
- 2 Reasons to Like MOH and 1 to Stay Skeptical
- Should Value Investors Buy Molina Healthcare (MOH) Stock?
- Oscar Health vs. Molina: Which Healthcare Stock Is a Better Buy?
- Oscar Health Trading at a Premium: Why Should You Still Buy It?
- UNH vs. MOH: Which Managed Care Stock Looks More Attractive?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Molina Healthcare Inc.
Full MOH Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.